A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.


Updates from The Motley Fool

Latest updates on Celgene from Fool.com.  The Fool has written over 800 articles on Celgene.
Should You Buy Celgene Stock?

Celgene's fallen out of favor with investors, but drugs currently in development might make buyin...

5 Top Stocks to Buy in May

The weather is heating up. These stocks could help your portfolio follow suit.



Stock Performance

View Interactive CELG Charts
Sponsored by

Key Data Points

Primary metrics and data points about Celgene.
Current Price: $79.59
Prev Close: $79.44
Open: $80.00
Bid: $79.65
Ask: $79.67
Day's Range: $78.57 - $80.15
52wk Range: $74.13 - $147.17
Volume: 3,204,181
Avg Vol 7,608,468
Market Cap: $63B
P/E (ttm): 22.13
EPS (ttm): $3.59
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Celgene.
CAPS Rating 5 out of 5
 
2309 Outperform
78 Underperform
CAPS All Stars
 
509 Outperform
13 Underperform

How do you think Celgene will perform against the market?



You pick for Celgene is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Mark J. Alles, CEO

86% Approve

Based on 66 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Celgene.

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers